Climb Bio
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 3 Sell calls were followed by a 22% average decline over the next quarter.
- Recent price momentum is +192.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 18.5% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -32.1% | Better than 12% |
| Return on invested capital | -36.5% | Better than 8% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -46.8% | Better than 7% |
| 6-month return | -16.5% | Better than 31% |
| 12-month return (ex latest month) | 520.0% | Better than 100% |
| Distance below 52-week high | 49.9% | Better than 19% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 15.2x | Better than 97% |
| Debt to assets | 0.3% | Better than 97% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 217.5% | Better than 95% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 9.28
- Open
- 8.98
- Day range
- 8.90 - 9.40
- Avg price
- 9.19
- Volume
- 770.18K
- Turnover
- 7.08M
- Turnover ratei
- 2.09%
- Volume ratioi
- 1.14
- Amplitudei
- 5.37%
- 52-week rangei
- 1.64 - 18.33
Valuation
- P/Ei
- -10.44
- P/E (TTM)i
- -11.35
- P/Bi
- 2.37
- EPSi
- -0.88
- Book value / shi
- 3.88
- Net profit
- -51.69M
- Net assets
- 228.08M
Share structure
- Market cap
- 539.80M
- Float capi
- 339.13M
- Shares out
- 58.74M
- Float sharesi
- 36.90M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-08-10
49.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-7.67M net over the window
Short interest
- Shares short
- 10.61M
- % of floati
- 18.48%
- Days to coveri
- 7.76
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Climb Bio (CLYM)?
Climb Bio last traded at 9.19. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Climb Bio's market cap?
About 539.80M.
What is the P/E ratio of Climb Bio?
The trailing twelve-month P/E is -11.35. The Valuation tab shows it against the stock's own five-year range.
Does Climb Bio pay a dividend?
Climb Bio does not currently pay a regular dividend.
Is Climb Bio a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 29.18, which implies 217.5% upside from the current price. This is not investment advice.
What is Climb Bio's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Climb Bio a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Climb Bio discussion 0 comments